Personalization of deep brain stimulation using local field potentials to drive adaptive DBS: a case series
Objective: To observe chronically recorded local field potentials (LFPs) in patients receiving Deep Brain Stimulation (DBS) for Parkinson’s Disease (PD) and using an adaptive DBS…Non-motor fluctuations in People with Parkinson’s considering Deep Brain Stimulation surgery
Objective: In this study we examine non-motor symptom (NMS) fluctuations reported by People with Parkinson’s (PWP) pursuing Deep Brain Stimulation (DBS) surgery using the MDS…Case reports of first experiences worldwide with novel continuous oral levodopa dental pump in Parkinson’s Disease Patients
Objective: To assess the safety, tolerability, and pharmacokinetics (PK) of a novel continuous levodopa-carbidopa oral pump (LCOP) delivery system in patients with early PD. Background:…Risk factors for the onset of dyskinesia in patients with Parkinson’s disease exhibiting wearing-off phenomena: A 1-year observational study in Japan (J-FIRST)
Objective: To investigate the risk factors for the onset of dyskinesia in patients with Parkinson's disease (PD) exhibiting wearing-off phenomena. Background: Dyskinesia occurs during long-term…Personality dimensions could be predictive of quality-of-life outcome after deep brain stimulation of the sub-thalamic nucleus in Parkinson’s Disease
Objective: Our objective was to evaluate associations between personality dimensions and Quality of Life (QoL) amelioration after one year of Deep Brain Stimulation of the…Feasibility to Detect Parkinson’s Motor Symptoms with a Waist-Worn Parkinson’s Holter
Objective: Analysis of the feasibility in the detection of Parkinson’s Motor Symptoms. Background: Usually, in current clinical practice, the physicians have a very limited slot…Should Amantadine DR/ER Be Considered Prior to Device-Aided Therapies for Parkinson’s Disease?
Objective: Evaluate delayed release/extended release amantadine (AMT DR/ER) capsules for motor complications in patients meeting 5-2-1 criteria for device-aided therapies (DAT) in advanced Parkinson disease.…CVT-301 (levodopa inhalation powder): meta-analysis of safety in patients with Parkinson’s disease (PD)
Objective: Safety results from a phase 3, double-blind study of CVT-301 in patients with PD were combined with results from a 4-week, phase 2b, double-blind,…Amantadine DR/ER-Related Reduction in OFF and Dyskinesia Improved Patient-Rated Interference with Activities and Social Interactions
Objective: Evaluate dyskinesia and OFF interference with activities and experiences for persons with Parkinson disease (PWPD), and mitigation with treatment Background: OFF and Dyskinesia remain…IMPACT OF STANDARD-OF-CARE MEDICATIONS ON TIME-OFF READOUTS IN CLINICAL TRIALS. A QUANTITATIVE SYSTEMS PHARMACOLOGY APPROACH
Objective: To mitigate clinical variability of Time-Off with various therapeutic combinations Background: There is increasing interest to use wearable-based digital health measures to continuously monitor…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 26
- Next Page »